Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to $620000.0.

  • Foghorn Therapeutics' Other Non Operating Income fell 4979.76% to $620000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 2416.3%. This contributed to the annual value of $4.2 million for FY2024, which is 4705.05% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Other Non Operating Income of $620000.0 as of Q3 2025, which was down 4979.76% from $852000.0 recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Other Non Operating Income ranged from a high of $1.4 million in Q4 2024 and a low of -$1.2 million during Q4 2021
  • Its 5-year average for Other Non Operating Income is $694105.3, with a median of $680000.0 in 2021.
  • Examining YoY changes over the last 5 years, Foghorn Therapeutics' Other Non Operating Income showed a top increase of 450714.29% in 2021 and a maximum decrease of 31276.6% in 2021.
  • Over the past 5 years, Foghorn Therapeutics' Other Non Operating Income (Quarter) stood at -$1.2 million in 2021, then soared by 152.0% to $624000.0 in 2022, then increased by 8.65% to $678000.0 in 2023, then surged by 107.37% to $1.4 million in 2024, then tumbled by 55.9% to $620000.0 in 2025.
  • Its Other Non Operating Income stands at $620000.0 for Q3 2025, versus $852000.0 for Q2 2025 and $1.4 million for Q1 2025.